Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Water. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 known ✓ | O00255 | 1/20 | 0.45 |
| ▸ | TTR | P02766 | 1/20 | 0.72 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.53 |
| ▸ | AURKA | O14965 | 1/20 | 0.50 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.50 |
| ▸ | CDK2 | P24941 | 1/20 | 0.50 |
| ▸ | COMT | P21964 | 1/20 | 0.46 |
| ▸ | APEX1 | P27695 | 1/20 | 0.45 |
| ▸ | NSD2 | O96028 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | IDE | P14735 | 1/20 | 0.45 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.45 |
| ▸ | CCR6 | P51684 | 1/20 | 0.45 |
| ▸ | BLM | P54132 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | ATIC | P31939 | 2/20 | 0.44 |
| ▸ | ALPL | P05186 | 1/20 | 0.44 |
| ▸ | ALPI | P09923 | 1/20 | 0.44 |
| ▸ | ALPG | P10696 | 1/20 | 0.44 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL29809771 | 1.00 | TTR (0.72) | TTRCYP1A2AURKAAURKBCDK2 | |
| Water SCHEMBL29893556 | 1.00 | TTR (0.72) | TTRCYP1A2AURKAAURKBCDK2 | |
| Water SCHEMBL11473359 | 1.00 | TTR (0.72) | TTRCYP1A2AURKAAURKBCDK2 | |
| Water SCHEMBL26654237 | 1.00 | TTR (0.72) | TTRCYP1A2AURKAAURKBCDK2 | |
| Water SCHEMBL31290656 | 1.00 | TTR (0.72) | TTRCYP1A2AURKAAURKBCDK2 | |
| Water SCHEMBL11360879 | 1.00 | TTR (0.72) | TTRCYP1A2AURKAAURKBCDK2 | |
| Water SCHEMBL242080 | 1.00 | TTR (0.72) | TTRCYP1A2AURKAAURKBCDK2 | |
| Water SCHEMBL26654218 | 0.97 | TTR (0.69) | TTRCYP1A2AURKAAURKBCDK2 | |
| Water SCHEMBL3919443 | 0.97 | TTR (0.69) | TTRCYP1A2AURKAAURKBCDK2 | |
| Water SCHEMBL31235665 | 0.97 | TTR (0.69) | TTRCYP1A2AURKAAURKBCDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111467346-B | Pyridone derivatives with tetrahydropyranylmethyl groups | 第一三共株式会社 | 2023-05-16 | — | — | CN | claimed |
| US-20120157446-A1 | MEDICAL USE | GLAXO GROUP LIMITED (GB) | 2012-06-21 | — | — | US | claimed |
| EP-2448586-A1 | NEW MEDICAL USE | Glaxo Group Limited (GB) | 2012-05-09 | — | — | EP | claimed |
| WO-2011000767-A1 | NEW MEDICAL USE | GLAXO GROUP LIMITED (GB) | 2011-01-06 | — | — | WO | claimed |
| EP-2007735-B1 | 2-SUBSTITUTED 4-BENZYLPHTHALAZINONE DERIVATIVES AS HISTAMINE H1 AND H3 ANTAGONISTS | GLAXO GROUP LTD (GB) | 2010-10-27 | — | — | EP | claimed |
| WO-2009153296-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A NON-STEROIDAL GLUCOCORTICOID RECEPTOR AGONIST IN COMBINATION WITH A DUAL HISTAMINE ANTAGONIST | GLAXO GROUP LIMITED (GB) | 2009-12-23 | — | — | WO | claimed |
| WO-2009050159-A1 | COMBINATION OF FLUTICASONE FUROATE WITH 4- [ (4-CHL0R0PHENYL)METHYL] -2- ({ (2R)-I- [4-(4-{ [3-(HEXAHYDR0-LH-AZEPIN-L-YL) PROPYL ] OXY} PHENYL) BUTYL] -2-PYRROLIDINYL}METHYL) -1 (2H) - PHTHALAZ INONE | GLAXO GROUP LIMITED (GB) | 2009-04-23 | — | — | WO | claimed |
| US-7470707-B2 | Crystalline monohydrate clopidogrel naphthalenedisulfonate and process of preparation | HANMI PHARM. CO., LTD (KR) | 2008-12-30 | — | — | US | claimed |
| US-20080039444-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2008-02-14 | — | — | US | claimed |
| EP-4054541-B1 | SALT FORMS OF A COMPLEMENT COMPONENT C5A RECEPTOR | CHEMOCENTRYX INC (US) | 2026-05-06 | — | — | EP | disclosed |
| CN-118284600-A | Pharmaceutically acceptable salts of irinotecan and crystalline forms thereof | 曙方(上海)医药科技有限公司 | 2024-07-02 | — | — | CN | disclosed |
| WO-2023159094-A2 | PROCESS OF MAKING 3α-HYDROXY-3β-METHOXYMETHYL-21-(1'- IMIDAZOLYL)-5α-PREGNAN-20-ONE | PRAXIS PRECISION MEDICINES, INC. (US) | 2023-08-24 | — | — | WO | disclosed |
| WO-2023083293-A1 | PHARMACEUTICALLY ACCEPTABLE SALT OF ELIGLUSTAT AND CRYSTAL FORM THEREOF | 曙方(上海)医药科技有限公司 | 2023-05-19 | — | — | WO | disclosed |
| CN-116120274-A | Pharmaceutically acceptable salts of irinotecan and crystalline forms thereof | 曙方(上海)医药科技有限公司 | 2023-05-16 | — | — | CN | disclosed |
| WO-2007122156-A9 | 2-SUBSTITUTED 4-BENZYLPHTHALAZINONE DERIVATIVES AS HISTAMINE H1 AND H3 ANTAGONISTS | GLAXO GROUP LTD (GB) | 2008-01-24 | — | — | WO | disclosed |
| WO-2007122156-A1 | 2-SUBSTITUTED 4-BENZYLPHTHALAZINONE DERIVATIVES AS HISTAMINE H1 AND H3 ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2007-11-01 | — | — | WO | disclosed |
| WO-2007108615-A1 | METHOD FOR PREPARING CLOPIDOGREL 1,5-NAPHTHALENEDISULFONATE OR HYDRATE THEREOF | HANMI PHARM. CO., LTD. (KR) | 2007-09-27 | — | — | WO | disclosed |
| EP-1732932-A1 | CRYSTALLINE CLOPIDOGREL NAPHTHALENESULFONATE OR HYDRATE THEREOF, METHOD FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | Hanmi Pharm. Co., Ltd. (KR) | 2006-12-20 | — | — | EP | disclosed |
| WO-2005097804-A1 | CRYSTALLINE CLOPIDOGREL NAPHTHALENESULFONATE OR HYDRATE THEREOF, METHOD FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | HANMI PHARM. CO., LTD. (KR) | 2005-10-20 | — | — | WO | disclosed |
| US-20050228012-A1 | Crystalline clopidogrel naphthalenesulfonate or hydrate thereof, method for preparing same and pharmaceutical composition containing same | HANMI PHARM. CO., LTD. | 2005-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050228012-A1 | Crystalline clopidogrel naphthalenesulfonate or hydrate thereof, method for preparing same and pharmaceutical composition containing same | P2RY6, NUDT1, AGPS | MEN1 3037/4885TTR 768/4885CYP1A2 166/4885 |
| US-20080039444-A1 | COMPOUNDS | CMA1, MRGPRX2, HRH2 | MEN1 621/4885TTR 2551/4885CYP1A2 67/4885 |
| US-20120157446-A1 | MEDICAL USE | HRH2, HRH4, HRH1 | MEN1 1746/4885TTR 3820/4885CYP1A2 675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.